GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of [Vendor] BCH vs KP on the same compound, same month — both cleared 98.5% — 14 comments in the full submission. View in context.
92
c/survodutide·submitted 3 months ago by u/cato_girard

[Vendor] BCH vs KP on the same compound, same month — both cleared 98.5%

Paperbranch of 6 comments

Result first, context after: BCH vs KP on the same compound, same month — both cleared 98.5% . Everything below is how it was ordered, stored and sent. Figures up front so nobody has to dig: 98.5%. Read the phase 2 hepatic paper properly and the endpoint definitions were more interesting than the headline response…

Read the full submission and all 14 comments →

This branch

6 comments, started 3 months ago
u/peak_area_peteanalytical11 points·3 months ago

glucagon agonism and energy expenditure is the mechanistic thread

replysharereportpermalink
u/patient_labslip_log7 points·3 months ago

Same. Very thin independent data on this one, which should make everybody here more tentative than they are.

replysharereportpermalink
u/nadia_bakker0 points·3 months ago

glucagon agonism and energy expenditure is the mechanistic thread

Adding the standing caveat — unapproved compound, research material is not for human use.

replysharereportpermalink
u/kaia_cabrera0 points·3 months ago

Adding the standing caveat — unapproved compound, research material is not for human use.

This is the framing the board needs. It is a hepatic programme first.

replysharereportpermalink
u/crosspost_bot_no8 points·3 months ago·edited

That figure is from the obesity programme, and this thread is about the hepatic one.

replysharereportpermalink
u/cold_chromatogram_only5 points·3 months ago

Asked here what the difference was between the imaging and biopsy endpoints and got a genuinely excellent answer.

replysharereportpermalink

← back to the whole thread

About c/survodutide

Survodutide-specific discussion: glucagon-receptor co-agonism, the hepatic fat and MASH resolution data, and how the side-effect profile compares with GIP-based dual agonism. Small community, high signal.

12kmembers
62submissions
Feb 2024created
submissions / month, last year
Sponsored

Sigma-Aldrich Standards

Certified reference materials for peptide identity and purity work.

sigmaaldrich.com
More in c/survodutide
c/survodutide rules
  1. Glucagon co-agonism has a distinct safety story. Do not generalise from tirzepatide.
  2. MASH claims need the trial and the biopsy endpoint.
  3. Not approved. Descriptive posts only.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/incretin_ivyu/liver_enzyme_lizu/trialwatch_theo
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →